Start: January 31, 2019
End: June 30, 2024
What Is This Study About?
This study will test the effects of memantine on brain function and dementia symptoms in older adults with mild to moderate Alzheimer's disease who are not currently taking Alzheimer's medications. Memantine, also known as Namenda, is a drug approved by the U.S. Food and Drug Administration to treat moderate to severe symptoms of Alzheimer's disease. In this study participants will be randomly assigned to take either memantine (20 mg) or a placebo twice daily for about six weeks.
Do I Qualify To Participate in This Study?
- Diagnosis of Alzheimer's disease
- Mini-Mental State Examination score of 10 to 22 or Montreal Cognitive Assessment score of 15 to 24
- Knowledgeable caregiver
- Able to walk
- Medically stable
- Pass hearing test
Must NOT have:
- Active systemic illness (e.g., heart disease, liver failure, kidney insufficiency, cancer, HIV, tuberculosis, hepatitis C)
- Current psychiatric or neurological illness other than Alzheimer's disease
- History of vascular disease, heart attack, cerebrovascular accidents, mini-stroke, seizure, head injury with loss of consciousness
- History of substance dependence, including alcohol and opioids
- Past treatment with memantine or unable to take an acetylcholinesterase inhibitor
- Participated in an investigational drug treatment within 30 days of screening
- Prohibited medications: amantadine, riluzole, other pro-cognitive drugs, opioids
- Positive urine test for nonprescribed psychoactive substance
- Actively enrolled in cognitive remediation therapy
If I Qualify, Who Do I Contact?
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Where Is This Study Located?
Clinical Teaching Facility (CTF-B102) at UCSD Medical Center
San Diego, CA 92103
Jo Talledo, B.A.
Lead: University of California, San Diego
Source: ClinicalTrials.gov ID: NCT03703856